The development and clinical use of oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes: dawn of the total oral therapy era-Reference-Cited by-同舟云学术

The development and clinical use of oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes: dawn of the total oral therapy era

Published:2021-04-28 Issue:9 Volume:21 Page:989-1002
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Schiffer Molly¹,Zhao Jennifer¹,Johnson Aubrey¹,Lee Jane¹,Bewersdorf Jan Philipp²^ORCID,Zeidan Amer M.³

Affiliation:

1. Department of Pharmacy, Yale New Haven Hospital, New Haven, CT, USA

2. Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA

3. Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, and Yale Cancer Center, New Haven, CT, USA

Funder

part supported by the National Cancer Institute of the National Institutes of Health under Award Number

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2021.1918002

Reference94 articles.

1. Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management

2. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

3. Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee

4. How I use molecular genetic tests to evaluate patients who have or may have myelodysplastic syndromes

5. Clinical and biological implications of driver mutations in myelodysplastic syndromes

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient Preferences for Benefits, Risks, and Administration Route of Hypomethylating Agents in Myelodysplastic Syndromes;Clinical Lymphoma Myeloma and Leukemia;2022-09

2. Hypomethylating Agents as Maintenance Therapy in the Treatment of Elderly Acute Myeloid Leukemia:A Meta-Analysis;SSRN Electronic Journal;2022

3. Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia;Leukemia;2021-06-26